CL2022003099A1 - Terapia génica con vectores duales de disferlina - Google Patents

Terapia génica con vectores duales de disferlina

Info

Publication number
CL2022003099A1
CL2022003099A1 CL2022003099A CL2022003099A CL2022003099A1 CL 2022003099 A1 CL2022003099 A1 CL 2022003099A1 CL 2022003099 A CL2022003099 A CL 2022003099A CL 2022003099 A CL2022003099 A CL 2022003099A CL 2022003099 A1 CL2022003099 A1 CL 2022003099A1
Authority
CL
Chile
Prior art keywords
dual
vectors
dysferlin
gene therapy
recombinant polynucleotides
Prior art date
Application number
CL2022003099A
Other languages
English (en)
Inventor
Rodino-Klapac Louise
Original Assignee
Res Inst Nationwide Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Inst Nationwide Childrens Hospital filed Critical Res Inst Nationwide Childrens Hospital
Publication of CL2022003099A1 publication Critical patent/CL2022003099A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4707—Muscular dystrophy
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/40—Systems of functionally co-operating vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

En el presente documento se describen polinucleótidos recombinantes que codifican fragmentos de una proteína disferlina humana. Además, se describen adicionalmente plásmidos, vectores virales, sistemas de vectores duales, células y composiciones que comprenden dichos polinucleótidos recombinantes. Dichos polinucleótidos recombinantes, plásmidos, vectores virales, sistemas de vectores duales, células y composiciones pueden usarse para tratar disferlinopatías.
CL2022003099A 2020-05-13 2022-11-08 Terapia génica con vectores duales de disferlina CL2022003099A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063024338P 2020-05-13 2020-05-13

Publications (1)

Publication Number Publication Date
CL2022003099A1 true CL2022003099A1 (es) 2023-10-13

Family

ID=78524926

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022003099A CL2022003099A1 (es) 2020-05-13 2022-11-08 Terapia génica con vectores duales de disferlina

Country Status (17)

Country Link
US (1) US20230279065A1 (es)
EP (1) EP4138999A4 (es)
JP (2) JP2023519762A (es)
KR (2) KR20230009444A (es)
CN (1) CN115605266A (es)
AR (1) AR123826A1 (es)
AU (2) AU2021270526B2 (es)
BR (1) BR112022020387A2 (es)
CA (1) CA3172664A1 (es)
CL (1) CL2022003099A1 (es)
CO (1) CO2022016968A2 (es)
IL (2) IL320715A (es)
MX (3) MX2022014066A (es)
MY (1) MY198257A (es)
NZ (1) NZ793468A (es)
TW (1) TW202208407A (es)
WO (1) WO2021231577A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL318484A (en) * 2022-07-21 2025-03-01 Univ New York AUF1 gene therapy for limb girdle muscular dystrophy
WO2025221969A2 (en) * 2024-04-18 2025-10-23 Sarepta Therapeutics, Inc. Genetic constructs for gene editing

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030110526A1 (en) * 1998-08-25 2003-06-12 Robert H. Brown Dysferlin mutations
WO2000011157A1 (en) * 1998-08-25 2000-03-02 The General Hospital Corporation Dysferlin, a gene mutated in distal myopathy and limb girdle muscular dystrophy
CN109563512A (zh) * 2016-06-17 2019-04-02 北卡罗来纳大学教堂山分校 用于治疗Dysferlin肌病的截短Dysferlin
US20200368162A1 (en) * 2017-02-24 2020-11-26 Modernatx, Inc. Nucleic Acid-Based Therapy of Muscular Dystrophies
WO2019210267A2 (en) * 2018-04-27 2019-10-31 Spark Therapeutics, Inc. Engineered aav capsids with increased tropism and aav vectors comprising the engineered capsids and methods of making and using same
CA3102936A1 (en) * 2018-08-10 2020-02-13 Unm Rainforest Innovations Methods of detecting inherited myopathies in horses

Also Published As

Publication number Publication date
AU2023206111B2 (en) 2026-02-26
MX2022014066A (es) 2022-12-07
MX2025001841A (es) 2025-03-07
JP2023519762A (ja) 2023-05-12
NZ793468A (en) 2023-07-28
EP4138999A1 (en) 2023-03-01
CO2022016968A2 (es) 2022-12-09
US20230279065A1 (en) 2023-09-07
IL297656B2 (en) 2025-10-01
AU2023206111A1 (en) 2023-08-10
JP7820422B2 (ja) 2026-02-25
AR123826A1 (es) 2023-01-18
IL297656A (en) 2022-12-01
MY198257A (en) 2023-08-17
KR20240074881A (ko) 2024-05-28
CN115605266A (zh) 2023-01-13
MX2025003591A (es) 2025-05-02
JP2024032967A (ja) 2024-03-12
IL297656B1 (en) 2025-06-01
CA3172664A1 (en) 2021-11-18
TW202208407A (zh) 2022-03-01
KR20230009444A (ko) 2023-01-17
BR112022020387A2 (pt) 2022-11-29
AU2021270526B2 (en) 2023-04-20
EP4138999A4 (en) 2024-01-10
AU2021270526A1 (en) 2022-11-24
IL320715A (en) 2025-07-01
WO2021231577A1 (en) 2021-11-18

Similar Documents

Publication Publication Date Title
CL2022003099A1 (es) Terapia génica con vectores duales de disferlina
MX2024015050A (es) L-asparaginasa modificada
MX2021009357A (es) Dianas de genes de combinacion para mejorar la inmunoterapia.
MX2017004664A (es) Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria.
AR112057A1 (es) Vectores virales que codifican variantes de fix recombinantes con mayor expresión para la terapia génica de hemofilia b
CO2020001654A2 (es) Proteínas de fijación al antígeno que se fijan a 5t4 y 4-1bb y composiciones y métodos relacionados
MX2021010543A (es) Receptores de linfocitos t y metodos de uso de estos.
ECSP22092206A (es) Ácido nucleico codón optimizado que codifica la proteina smn1 y su uso
BR112021017486A2 (pt) Receptores de células t e métodos de uso dos mesmos
MX2021010539A (es) Receptores de linfocitos t y metodos de uso de estos.
BR112022010095A2 (pt) Proteínas gpcr de opsina quimérica
BR112021017505A2 (pt) Receptores de células t e métodos de uso dos mesmos
BR112021017491A2 (pt) Receptores de células t e métodos de uso dos mesmos
BR112023018430A2 (pt) Terapias gênicas para deficiência de 21-hidroxilase
CL2020002246A1 (es) Expresión de proteína de superficie a neumocócica (pspa)
CO2020000231A2 (es) Composiciones inmunogénicas que comprenden cea muc1 y tert
BR112023023032A2 (pt) Redirecionamento universal do hsv oncolítico
BR112015023263A2 (pt) clonagem e uso do gene ms9 do milho
BR112022001697A2 (pt) Receptores de células t e métodos de uso dos mesmos
MX2023011588A (es) Constructos y metodos para aumentar la expresion de polipeptidos.
PY2215552A (es) Ácido nucleico optimizado por codones que codifica la proteína del factor de coagulación ix, y su uso
PY2331315A (es) Ácido nucleico de codón optimizado que codifica la proteína del factor viii de coagulación de dominio b suprimido, y uso del mismo
AR120198A1 (es) Construcciones de variantes de igf2
AR112757A1 (es) Composiciones inmunogénicas
AR101293A1 (es) Célula hospedadora mejorada para producir proteínas